• +1-646-491-9876
    • +91-20-67278686

    Search

    Beta Secretase 1-Pipeline Review H1 2017

    Beta Secretase 1-Pipeline Review H1 2017

    • Report Code ID: RW0001834341
    • Category Pharmaceuticals
    • No. of Pages 77
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Pipeline Review, H1 2017

    Summary

    Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Beta-secretase 1 (BACE1) is an enzyme that in humans is encoded by the BACE1 gene. It is responsible for the proteolytic processing of the amyloid precursor protein (APP) . It cleaves at the N-terminus of the A-beta peptide sequence of APP. This leads to the generation and extracellular release of beta-cleaved soluble APP and a corresponding cell-associated C-terminal fragment which is later released by gamma-secretase.

    Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) pipeline Target constitutes close to 26 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 5, 1, 1 and 12 respectively. Similarly, the universities portfolio in Phase I and Preclinical stages comprises 1 and 6 molecules, respectively. Report covers products from therapy areas Central Nervous System which include indications Alzheimer's Disease, Dementia Associated With Alzheimer's Disease, Mild Cognitive Impairment and Neurodegenerative Diseases.

    The latest report Beta Secretase 1 - Pipeline Review,, outlays comprehensive information on the Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA) , route of administration (RoA) and molecule type. It also reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics development with respective active and dormant or discontinued projects.

    The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

    Scope

    - The report provides a snapshot of the global therapeutic landscape for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)
    - The report reviews Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
    - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
    - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
    - The report reviews key players involved in Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics and enlists all their major and minor projects
    - The report assesses Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics based on mechanism of action (MoA) , route of administration (RoA) and molecule type
    - The report summarizes all the dormant and discontinued pipeline projects
    - The report reviews latest news and deals related to Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) targeted therapeutics

    Reasons to buy

    - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
    - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
    - Identify and understand the targeted therapy areas and indications for Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46)
    - Identify the use of drugs for target identification and drug repurposing
    - Identify potential new clients or partners in the target demographic
    - Develop strategic initiatives by understanding the focus areas of leading companies
    - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
    - Devise corrective measures for pipeline projects by understanding Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) development landscape
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Overview
    Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Therapeutics Development
    Products under Development by Stage of Development
    Products under Development by Therapy Area
    Products under Development by Indication
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Therapeutics Assessment
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Companies Involved in Therapeutics Development
    Allergan Plc
    Amgen Inc
    AstraZeneca Plc
    Bristol-Myers Squibb Company
    Eisai Co Ltd
    Eli Lilly and Company
    Genentech Inc
    H. Lundbeck A/S
    Johnson & Johnson
    Merck & Co Inc
    Novartis AG
    Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Drug Profiles
    AMG-8718 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AVCRI-104P3 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AVCRI-175P1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    AZ-4217 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CNP-520 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    elenbecestat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    ER-901356 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GNE-892 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    JNJ-54861911 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    lanabecestat camsylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LuAF-66432 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LY-2811376 + LY-3002813 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    LY-3202626 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Oligonucleotides to Activate miR-188-3p for Alzheimer's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit BACE 1 for Alzheimer's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit BACE1 for Alzheimer's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit BACE1 for Alzheimer's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit APP-Selective BACE Enzyme for Alzheimer's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit BACE-1 and GSK-3 Beta for Alzheimer's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit BACE1 for Alzheimer Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit BACE1 for Alzheimer's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Inhibit Beta Secretase 1 for Alzheimer's Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAK-070 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    verubecestat - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VTP-36951 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Dormant Products
    Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Discontinued Products
    Beta Secretase 1 (Aspartyl Protease 2 or Beta Site Amyloid Precursor Protein Cleaving Enzyme 1 or Memapsin 2 or Membrane Associated Aspartic Protease 2 or BACE1 or EC 3.4.23.46) - Product Development Milestones
    Featured News & Press Releases
    Mar 29, 2017: Enrollment Commences In Phase III Clinical Study Of Eisai's Bace Inhibitor Elenbecestat In Early Alzheimer's Disease In Japan
    Feb 14, 2017: Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer's Disease to Stop for Lack of Efficacy
    Dec 12, 2016: Eisai Presents Latest Data On Bace Inhibitor Elenbecestat (E2609) At 9Th Clinical Trials On Alzheimer's Disease
    Nov 18, 2016: U.S. FDA Grants Fast Track Designation For The Development Of Eisai's Bace Inhibitor E2609 For Early Alzheimer'S Disease
    Nov 02, 2016: Merck Scientists Publish New Research Detailing the Early Development of Verubecestat, an Investigational BACE1 Inhibitor in Science Translational Medicine
    Oct 31, 2016: Enrollment Commences In Phase III Clinical Study Of Eisai's Bace Inhibitor E2609 In Early Alzheimer's Disease
    Aug 22, 2016: Lilly and AstraZeneca Receive FDA Fast Track Designation for AZD3293, an Investigational Treatment for Early Alzheimer's Disease
    Aug 09, 2016: U.S. FDA Confirms Sufficient Data to Advance Investigational Bace Inhibitor E2609 for Treatment of Early Alzheimer's Disease to Phase III
    Jun 14, 2016: New Alzheimers Study Aimed at Preventing or Delaying Symptoms
    Apr 08, 2016: AstraZeneca and Eli Lilly and Company announce continuation of pivotal clinical trial for people with early Alzheimer's disease
    Jan 28, 2016: Merck Completes Enrollment in Pivotal Phase 3 "EPOCH" Trial Investigating the Efficacy and Safety of Verubecestat in Patients with Mild-to-Moderate Alzheimer's Disease
    Dec 01, 2014: AstraZeneca and Eli Lilly and Company initiate pivotal clinical trial for patients with early Alzheimer's disease
    May 07, 2014: AstraZeneca In Discussions For Partnership To Develop Alzheimer's Drug
    Dec 10, 2013: Merck Advances Development Program for Investigational Alzheimer's Disease Therapy, MK-8931
    Jul 14, 2013: Merck Presents Findings from Phase 1b Study of Investigational BACE Inhibitor, MK-8931, in Patients with Alzheimer's Disease
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by Therapy Areas, H1 2017
    Number of Products under Development by Indication, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017 (Contd..1) , H1 2017
    Number of Products under Investigation by Universities/Institutes, H1 2017
    Products under Investigation by Universities/Institutes, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Route of Administration, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Pipeline by Allergan Plc, H1 2017
    Pipeline by Amgen Inc, H1 2017
    Pipeline by AstraZeneca Plc, H1 2017
    Pipeline by Bristol-Myers Squibb Company, H1 2017
    Pipeline by Eisai Co Ltd, H1 2017
    Pipeline by Eli Lilly and Company, H1 2017
    Pipeline by Genentech Inc, H1 2017
    Pipeline by H. Lundbeck A/S, H1 2017
    Pipeline by Johnson & Johnson, H1 2017
    Pipeline by Merck & Co Inc, H1 2017
    Pipeline by Novartis AG, H1 2017
    Dormant Projects, H1 2017
    Discontinued Products, H1 2017

    List of Figures

    Number of Products under Development by Stage of Development, H1 2017
    Number of Products under Development by ndications, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Stage and Routes of Administration, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Allergan Plc
    Amgen Inc
    AstraZeneca Plc
    Bristol-Myers Squibb Company
    Eisai Co Ltd
    Eli Lilly and Company
    Genentech Inc
    H. Lundbeck A/S
    Johnson & Johnson
    Merck & Co Inc
    Novartis AG

    Request for Sample

    Report Url https://www.reportsweb.com//beta-secretase-1-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//beta-secretase-1-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//beta-secretase-1-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments